Growth hormone deficiency (GHD) specialists Sara DiVall, MD, and Kevin Yuen, MD, explore ways to optimize outcomes in the diagnosis and treatment of GHD in children, including considerations for the use of long-acting growth hormone (LAGH) products. Topics include the epidemiology, clinical manifestations, and burden of GHD in children and adolescents, evidence-based diagnosis of GHD, guidelines and recommendations for treatment, integrating shared decision-making with patients and/or their parents to develop and modify the treatment plan, and clinical trial data regarding daily and new and emerging LAGH products.  Case studies based on common clinical scenarios are discussed to examine how to apply this information in clinical practice to optimize long-term self-management.

Editor's Note: The faculty for this activity has disclosed that there is discussion about the use of products for non-FDA approved applications.

Presenting Faculty

• 

  Sara DiVall, MD

  Associate Professor of Pediatrics
  Fellowship Director
  Seattle Children’s Hospital
  Seattle, Washington

• 

  Kevin Yuen, MD

  Medical Director
  Barrow Pituitary Center
  Barrow Neuroendocrine Clinic
  Phoenix, Arizona